When preparing your IM injection, draw up the prescribed amount (for example, 1 mL) into the syringe
And (4) PRP is autologous and generally safe, which is reassuring for patients concerned about foreign substances
Leucine carboxyl methyltransferase downregulation and protein phosphatase methylesterase upregulation contribute toward the inhibition of protein phosphatase 2A by alpha-synuclein
Phase 2 and Phase 3 trial data Major clinical trials: Phase 2 (24-week trial, 2008): 203 obese participants Three dose groups: 0.25mg, 0.5mg, 1.0mg daily Placebo-controlled, randomized Primary outcome: Weight loss percentage Phase 2 results: Key findings: Dose-dependent weight loss 1mg dose: Average 23 lbs lost (starting weight ~220 lbs) Best responders: 15-20% weight loss Comparable to semaglutide 2.4mg But higher dropout due to side effects Phase 3 trials (planned but never completed): Intended for FDA approval Halted due to cardiovascular concerns Increased heart rate 5-10 bpm average Blood pressure elevation 2-5 mmHg Risk-benefit ratio questioned Development suspended 2010 Long-term data (limited): 1-year extension studies showed sustained loss Weight plateau at 6-9 months Some regain if discontinued No controlled trials beyond 1 year Safety concerns prevented longer studies Compare to semaglutide trials and tirzepatide results
Its use covers: Preparing single-dose medications safely Mixing powdered antibiotics in hospital settings Reconstituting drugs for immediate injection Supporting IV therapy in patient care These applications highlight the importance of such sterile solution or water in safe medical treatment
Available from: Sinha RA, Bruinstroop E, Singh BK, Yen PM
